Keywords: Novartis, Glivec, Gleevec, Patent, India Supreme Court, Evergreening

Novartis' imatinib patent battle resumes in Indian Supreme Court

Article | 15 August 2011

Print This

The controversial Novartis case in which the Swiss major Novartis (NOVN: VX) challenged the manner in which Section 3(d) of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in